SK Chemicals is partnering with J2H Biotech to co-develop a treatment for metabolic-associated fatty liver disease (MASH). The collaboration will focus on global development based on a candidate that has completed Phase 2a clinical trials.
On June 29, SK Chemicals announced that it has signed a letter of intent (LOI) with J2H Biotech for the domestic and international development and commercialization of the MASH treatment candidate 'J2H-1702.' This partnership follows a memorandum of understanding (MOU) signed in March, which has now progressed to a formal co-development phase after a review of technology and business viability.
J2H-1702 is an oral 11β-HSD1 inhibitor developed by J2H Biotech. The compound works by regulating cortisol metabolism, which helps inhibit fat accumulation, inflammation, and fibrosis progression. Initial results from the Phase 2a trials indicated a reduction in liver fat and potential anti-fibrotic effects.
The two companies plan to outline clinical and development strategies for both domestic and international markets, as well as establish a phased commercialization plan.
The global market for MASH treatments is rapidly expanding. According to the market research firm DataM Intelligence, the MASH treatment market is projected to grow from $7.8 billion in 2024 to $31.8 billion by 2033.
Park Hyun-sun, business representative of SK Chemicals, stated, "We will expand our new drug pipeline by collaborating with companies that possess expertise and technology in areas with limited treatment options."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.